The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity | MicrobiomeTrials← Back to trialsNCT07897409
The Impact of Using Nicorandil for the Prevention of Doxorubicin-Induced Cardiotoxicity
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-10-01Est. Completion: 2027-06-01
Enrollment target: 146 participants Locations- National Cancer Institute, Cairo, Cairo Governorate, Egypt
Other microbiome trials you might be interested in
Breast CancerDoxorubicin Induced Cardiomyopathy
the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with dox…
Beheira, EgyptCompleted Oct 20, 2024
Breast Cancer
Background:
Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbid…
Tanta, EgyptEst. completion Nov 1, 2027